News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
401,815 Results
Type
Article (17520)
Company Profile (131)
Press Release (384164)
Section
Business (135735)
Career Advice (866)
Deals (24638)
Drug Delivery (67)
Drug Development (47669)
Employer Resources (70)
FDA (8654)
Job Trends (8620)
News (220780)
Policy (18701)
Tag
Academia (688)
Alliances (31314)
Alzheimer's disease (529)
Approvals (8656)
Artificial intelligence (83)
Bankruptcy (204)
Best Places to Work (6127)
Biotechnology (63)
Breast cancer (79)
Cancer (607)
Career advice (742)
Cell therapy (111)
Clinical research (39411)
Collaboration (250)
Compensation (141)
COVID-19 (966)
C-suite (84)
Data (656)
Diabetes (80)
Diagnostics (2808)
Drug pricing (64)
Earnings (57025)
Employer resources (65)
Events (62255)
Executive appointments (301)
FDA (8967)
Funding (209)
Gene therapy (91)
GLP-1 (361)
Government (1602)
Healthcare (7419)
Infectious disease (996)
Interviews (108)
IPO (10939)
Job creations (2741)
Job search strategy (680)
Layoffs (254)
Legal (5040)
Lung cancer (79)
Manufacturing (133)
Medical device (4662)
Medtech (4665)
Mergers & acquisitions (13805)
Metabolic disorders (241)
Neuroscience (675)
NextGen Class of 2024 (2856)
Non-profit (1183)
Northern California (881)
Obesity (135)
Opinion (141)
Patents (67)
People (40385)
Pharmaceutical (69)
Phase I (10931)
Phase II (16927)
Phase III (14358)
Pipeline (361)
Postmarket research (1728)
Preclinical (4387)
Press Release (72)
Radiopharmaceuticals (170)
Rare diseases (135)
Real estate (3773)
Regulatory (12777)
Research institute (782)
Resumes & cover letters (126)
Southern California (776)
Startups (2209)
United States (7952)
Vaccines (140)
Weight loss (94)
Date
Today (1)
Last 7 days (327)
Last 30 days (1242)
Last 365 days (19534)
2024 (19440)
2023 (22809)
2022 (31095)
2021 (32578)
2020 (30639)
2019 (23684)
2018 (18364)
2017 (19761)
2016 (18575)
2015 (22497)
2014 (18492)
2013 (15579)
2012 (16767)
2011 (17458)
2010 (16480)
Location
Africa (437)
Arizona (77)
Asia (26104)
Australia (3458)
California (1965)
Canada (908)
China (160)
Colorado (91)
Connecticut (97)
Europe (52937)
Florida (279)
Illinois (186)
Indiana (129)
Japan (64)
Kansas (63)
Maryland (252)
Massachusetts (1654)
Michigan (82)
Minnesota (137)
New Jersey (702)
New York (551)
North Carolina (449)
Northern California (881)
Ohio (68)
Pennsylvania (457)
South America (665)
Southern California (776)
Texas (269)
Washington State (161)
401,815 Results for "novartis pharmaceutical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphyoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™
December 16, 2024
·
3 min read
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
Drug pricing
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.
October 21, 2024
·
2 min read
·
Tristan Manalac
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
Approvals
Novartis Secures First-Line CML Expansion for Scemblix, Projects $3B in Peak Sales
Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic myeloid leukemia. The expanded indication increases the eligible patient population by approximately four times, according to Novartis.
October 30, 2024
·
2 min read
·
Tristan Manalac
Approvals
Novartis Pushes Kisqali Into Earlier Stages of Breast Cancer, Nearly Doubles Eligible Patient Population
The FDA’s approval of Kisqali in combination with an aromatase inhibitor allows Novartis to target patients with earlier breast cancer who are at risk of recurrence.
September 18, 2024
·
2 min read
·
Tristan Manalac
1 of 40,182
Next
